Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Jun 2.

Published in final edited form as: Lung Cancer. 2014 Jun 16;85(2):282–292. doi: 10.1016/j.lungcan.2014.05.025

Fig. 2 — LATS2 protein expression in AD tumors and cell lines. (A) Before transfection, LATS2 protein expression was measured in each cell lines. (B) Cells were transfected with siRNA for LATS2 (siLATS2), Negative Control siRNA (siCont) or none (Mock Control) for 48hr. Number below each blot indicates fold change to mock control (n = 3). (C) Immunohistochemistry staining of LATS2 expression in clinical samples of AD. Female cases bearing EGFR mutations had moderately lower expression of LATS2 in the cytoplasm (mean expression value, 77.7 vs. 92.5, p = 0.031).

Fig. 2 — LATS2 protein expression in AD tumors and cell lines. (A) Before transfection, LATS2 protein expression was measured in each cell lines. (B) Cells were transfected with siRNA for LATS2 (siLATS2), Negative Control siRNA (siCont) or none (Mock Control) for 48hr. Number below each blot indicates fold change to mock control (n = 3). (C) Immunohistochemistry staining of LATS2 expression in clinical samples of AD. Female cases bearing EGFR mutations had moderately lower expression of LATS2 in the cytoplasm (mean expression value, 77.7 vs. 92.5, p = 0.031).